US 12,133,842 B2
Stable preservative-free mydriatic and anti-inflammatory solutions for injection
Gregory A. Demopulos, Mercer Island, WA (US); Hui-rong Shen, Bothell, WA (US); and Clark E. Tedford, Poulsbo, WA (US)
Assigned to Rayner Intraocular Lenses Limited, Worthing (GB)
Filed by RAYNE INTRAOCULAR LENSES LIMITED, Worthing (GB)
Filed on Dec. 16, 2021, as Appl. No. 17/552,872.
Application 17/552,872 is a continuation of application No. 17/405,269, filed on Aug. 18, 2021, abandoned.
Application 17/405,269 is a continuation of application No. 17/171,373, filed on Feb. 9, 2021, abandoned.
Application 17/171,373 is a continuation of application No. 16/944,609, filed on Jul. 31, 2020, abandoned.
Application 16/944,609 is a continuation of application No. 16/738,546, filed on Jan. 9, 2020, abandoned.
Application 16/738,546 is a continuation of application No. 16/454,775, filed on Jun. 27, 2019, abandoned.
Application 16/454,775 is a continuation of application No. 16/213,758, filed on Dec. 7, 2018, abandoned.
Application 16/213,758 is a continuation of application No. 15/823,282, filed on Nov. 27, 2017, abandoned.
Application 15/823,282 is a continuation of application No. 15/278,514, filed on Sep. 28, 2016, granted, now 9,855,246, issued on Jan. 2, 2018.
Application 15/278,514 is a continuation of application No. 14/721,151, filed on May 26, 2015, granted, now 9,486,406, issued on Nov. 8, 2016.
Application 14/721,151 is a continuation of application No. 14/061,039, filed on Oct. 23, 2013, granted, now 9,066,856, issued on Jun. 30, 2015.
Claims priority of provisional application 61/736,179, filed on Dec. 12, 2012.
Claims priority of provisional application 61/718,026, filed on Oct. 24, 2012.
Prior Publication US 2022/0175726 A1, Jun. 9, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/407 (2006.01); A61K 9/00 (2006.01); A61K 31/137 (2006.01); A61K 31/138 (2006.01)
CPC A61K 31/407 (2013.01) [A61K 9/0048 (2013.01); A61K 31/137 (2013.01); A61K 31/138 (2013.01)] 10 Claims
 
1. A liquid pharmaceutical dosage form comprising phenylephrine, ketorolac, a buffer system, an intraocular irrigation carrier and an inert gas overlay in a single-use container, wherein the phenylephrine is included at a concentration of from 30 to 720 μM and the ketorolac is included at a concentration of from 10 to 270 μM.